| Dr Doyle D Detweiler, MD | |
|
600 Medical Center Dr, Newton, KS 67114-8780 | |
| (316) 283-2700 | |
| (316) 804-6262 |
| Full Name | Dr Doyle D Detweiler |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 28 Years |
| Location | 600 Medical Center Dr, Newton, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063490233 | NPI | - | NPPES |
| 105667 | Other | KS | BLUE SHIELD PROVIDER NUMB |
| 111178 | Other | KS | BLUE SHIELD GROUP NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 0427014 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Newton Medical Center | Newton, KS | Hospital |
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| St Luke Hospital & Living Center | Marion, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apogee Medical Group Kansas Pa | 5294044715 | 11 |
News Archive
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
The wheelAIR cooling backrest cushion was offered a £75K investment deal by four Dragons on the latest episode of Dragons' Den after hearing a pitch by Staels Design's Managing Director Corien Staels.
A study conducted by researchers in the US has revealed that optimization of codon for bacterial expression causes the production of an inactive enzyme non-structural protein 12 (Nsp12), a catalytic subunit of RNA-dependent RNA polymerase of SARS-CoV-2.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
Senators working feverishly to pass health reform ahead of Congress' August recess raised doubts Wednesday on whether they will be able to pass reform on schedule, The Boston Globe reports.
› Verified 5 days ago
| Entity Name | Newton Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871588533 PECOS PAC ID: 5294646477 Enrollment ID: O20050917000300 |
News Archive
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
The wheelAIR cooling backrest cushion was offered a £75K investment deal by four Dragons on the latest episode of Dragons' Den after hearing a pitch by Staels Design's Managing Director Corien Staels.
A study conducted by researchers in the US has revealed that optimization of codon for bacterial expression causes the production of an inactive enzyme non-structural protein 12 (Nsp12), a catalytic subunit of RNA-dependent RNA polymerase of SARS-CoV-2.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
Senators working feverishly to pass health reform ahead of Congress' August recess raised doubts Wednesday on whether they will be able to pass reform on schedule, The Boston Globe reports.
› Verified 5 days ago
| Entity Name | Apogee Medical Group Kansas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831568450 PECOS PAC ID: 5294044715 Enrollment ID: O20151023002441 |
News Archive
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
The wheelAIR cooling backrest cushion was offered a £75K investment deal by four Dragons on the latest episode of Dragons' Den after hearing a pitch by Staels Design's Managing Director Corien Staels.
A study conducted by researchers in the US has revealed that optimization of codon for bacterial expression causes the production of an inactive enzyme non-structural protein 12 (Nsp12), a catalytic subunit of RNA-dependent RNA polymerase of SARS-CoV-2.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
Senators working feverishly to pass health reform ahead of Congress' August recess raised doubts Wednesday on whether they will be able to pass reform on schedule, The Boston Globe reports.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Doyle D Detweiler, MD 600 Medical Center Dr, Newton, KS 67114-8780 Ph: (316) 283-2700 | Dr Doyle D Detweiler, MD 600 Medical Center Dr, Newton, KS 67114-8780 Ph: (316) 283-2700 |
News Archive
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
The wheelAIR cooling backrest cushion was offered a £75K investment deal by four Dragons on the latest episode of Dragons' Den after hearing a pitch by Staels Design's Managing Director Corien Staels.
A study conducted by researchers in the US has revealed that optimization of codon for bacterial expression causes the production of an inactive enzyme non-structural protein 12 (Nsp12), a catalytic subunit of RNA-dependent RNA polymerase of SARS-CoV-2.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
Senators working feverishly to pass health reform ahead of Congress' August recess raised doubts Wednesday on whether they will be able to pass reform on schedule, The Boston Globe reports.
› Verified 5 days ago